SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to its anticipated inclusion in the S&P 500, sparking excitement among investors who foresee potential institutional investment and a price surge akin to Palantir's after its inclusion. The community is actively discussing potential short squeezes, target prices, and the impact of the upcoming company summit and potential Federal Reserve rate cuts on the stock's performance. Some investors are cautioning against excessive optimism, citing previous instances where stocks experienced declines post-inclusion.

Aventus

Aventus is trending, with community members highlighting a new partnership with The Truth Network. Bullish sentiment seems to be building with anticipation of a potential listing on a top 10 exchange. Some traders are pointing to the token's low market cap and limited supply as factors that could drive price appreciation.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is trending as investors weigh its dividend yield against recent market performance, with some expressing frustration over underperformance compared to growth-focused ETFs. The community is actively debating whether to hold SCHD for long-term income or rotate into higher-growth opportunities, especially as some point to its heavy weighting in energy and healthcare sectors. Recent discussions also highlight anticipation for the next dividend announcement and how broader economic factors like interest rate cuts and potential tariffs might impact the ETF.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as holders actively discuss earning Solana ($SOL.X) rewards simply by holding the token, highlighting its potential as a passive income source. The community is also excited about the upcoming Bare Knuckle Fighting Championship (BKFC) event featuring Kimbo Slice Jr., who will be representing $IMG.X, signaling a move towards broader brand visibility and community engagement.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around its potential, citing ongoing developments and a strong, active community. The coin, built on the Solana network, is experiencing increased attention, with community members celebrating new all-time highs. Discussions also highlight upcoming airdrops and staking features, generating excitement for the project's future.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors discuss its potential for growth, particularly following a recent analyst upgrade from Raymond James. Community members are focused on price targets, with some anticipating a rise to $25 next week and $50 in the near future. The stock's behavior around the $22 level is also a key talking point, with many hoping it can sustain gains.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is trending as traders discuss its potential upside and key resistance levels, with some eyeing it as a safe haven amid market uncertainty. Community members are actively considering options strategies and anticipating a run toward specific price targets, while also monitoring news related to analyst ratings and potential tariff impacts. Broader discussions involve P&G's role as a defensive stock and its established history of dividend increases.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to its inclusion in the S&P 500, sparking excitement and after-hours gains. The community is discussing the potential for continued momentum and profit-taking strategies, while some caution that index inclusion doesn't guarantee long-term success and insiders may soon sell shares. Applovin will replace MarketAxess in the S&P 500.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is currently a hot topic with community members debating its potential for growth and whether it's undervalued compared to other cryptocurrencies like ETH. Discussions also involve staking rewards and upcoming catalysts, such as potential ETF approvals. Despite mixed sentiment, some believe DOT is poised for a significant rally, while others express concerns about its performance.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as chatter revolves around potential acquisition bids and analyst optimism for their drug candidate, AXPAXLI, despite recent market volatility. Community members speculate on buyout prices and partnerships, focusing on the upcoming SOL-1 data and its potential impact on valuation. Some traders are weighing OCUL against competitors in the wet AMD space, while others discuss the broader biotech sector trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +61.29% and +17.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Gains 35% in 3 Months: How Should You Play the Stock?

MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?

FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mirumpharma.com/news-events/News/news-details/2025/Mirums-LIVMARLI-Now-FDA-Approved-in-Tablet-Formulation/default.aspx">announced</a> that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of its drug Livmarli for the treatment of cholestatic pruritus in patients with certain liver diseases.Livmarli is an orally administered ileal bile acid transporter inhibitor. It is used to treat cholestatic pruritus or intense itching caused by impaired bile flow in patients with rare liver diseases called Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).Mirum President Peter Radovich said that the approval for Livmarli in tablet form provides a “meaningful additional treatment option” for patients with ALGS and PFIC.He said that while younger patients can use liquid dosing, older patients can use a one-tablet-per-dose option. He added that the company has had “tremendous success” with Livmarli since launch.In 2024, Livmarli's net product <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mirumpharma.com/news-events/News/news-details/2025/Mirum-Pharmaceuticals-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Business-Update/default.aspx">sales</a> totaled $213.3 million, accounting for a whopping 63% of the company’s total net product sales.The tablets are expected to be available in June through Mirum Access Plus pharmacy.On Stocktwits, retail sentiment around Mirum Pharmaceuticals jumped further into the ‘bullish’ territory while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:649/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_2_10_41_PM_png_a632468a1b.webp" alt="MIRM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 14, 2025 | Source: Stocktwits" width="649" height="149"><figcaption>MIRM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the shares have been forming a “good base” since last year and stand the potential of touching $60.<stembedurl>https://stocktwits.com/buddyopalosam/message/611569108</stembedurl><a href="https://stocktwits.com/symbol/MIRM">MIRM stock</a> is down by over 6% year-to-date but has gained over 64% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cara-therapeutics-announces-1-for-3-reverse-stock-split/chfCXBzRbaQ">Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish

Livmarli tablets will be available in June through Mirum Access Plus pharmacy.

Equity

Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLI (chenodiol) tablets, a bile acid, for the treatment of adults with...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

MIRM
Mirum Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MIRM News

MIRM Mirum Pharmaceuticals Inc